Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

[1]  J. Ferlay,et al.  Cancer incidence and mortality in Europe, 2004. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Dimopoulos,et al.  Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Baselga,et al.  New drugs and new approaches in metastatic bladder cancer. , 2003, Critical reviews in oncology/hematology.

[4]  L. Collette,et al.  Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Redman,et al.  Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Baselga,et al.  Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Scher,et al.  Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract , 2000, Cancer.

[9]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Bacik,et al.  Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Geller,et al.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.

[14]  N. Geller,et al.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.

[15]  Peter Boyle,et al.  Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.